Drug
Marizomib
Marizomib is a pharmaceutical drug with 6 clinical trials. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_2
2
33%
Ph phase_1
2
33%
Ph phase_3
1
17%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(2)
Terminated(3)
Other(1)
Detailed Status
Terminated2
Completed2
unknown1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
unknown117%
terminated233%
completed233%
withdrawn117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_3
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT03345095
withdrawnphase_2
Marizomib Central Nervous System (CNS)
NCT05050305
terminatedphase_1
Phase I Study of Marizomib + Panobinostat for Children With DIPG
NCT04341311
terminatedphase_2
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
NCT03727841
unknown
Expanded Access for Marizomib
NCT04644107
Clinical Trials (6)
Showing 6 of 6 trials
NCT03345095Phase 3
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT05050305Phase 2
Marizomib Central Nervous System (CNS)
NCT04341311Phase 1
Phase I Study of Marizomib + Panobinostat for Children With DIPG
NCT03727841Phase 2
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
NCT04644107
Expanded Access for Marizomib
NCT02103335Phase 1
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6